Fatty liver disease (MASLD/MASH) trials in South Korea

In South Korea 15 Also abroad 367

15 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Where
Daegu, Goyang-si, Incheon, Seongnam-si, Seoul
Age
18 years to 80 years
People
1,650 worldwide
Run by
Akero Therapeutics, Inc
See details and how to joinNCT06215716
Phase 3Taking people
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Where
Bucheon-si, Busan, Deagu, Incheon, Seoul, Wŏnju
Age
18 years and over
People
1,800 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00
Phase 3Taking people
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Where
Bucheon-si, Busan, Incheon, Seoul, Wŏnju
Age
18 years and over
People
1,590 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Where
Busan, Daegu, Gyeonggi-do, Incheon, Seoul
Age
18 years to 80 years
People
1,350 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06318169 · EU 2023-509912-27-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Where
Bucheon-si, Busan, Daegu, Incheon, Seoul
Age
18 years to 75 years
People
1,800 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06419374 · EU 2023-510395-31-00
Phase 3Taking people
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Where
Daegu, Goyang-si, Incheon, Seoul, Wŏnju
Age
18 years to 80 years
People
2,150 worldwide
Run by
Akero Therapeutics, Inc
See details and how to joinNCT06528314
Phase 2Taking people
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Where
Busan, Daegu, Seongnam-si, Seoul
Age
18 years to 75 years
People
120 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT05519475
Phase 3Taking people
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Where
Ansan-si, Bucheon-si, Busan, Daegu, Dongjak-gu, Guri-si, Incheon, Jinju, Junggu, Seoul, Wŏnju
Age
18 years and over
People
4,500 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00
No phaseTaking people
Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
Where
Daejeon
Age
19 years and over
People
3,000
Run by
Chungnam National University Hospital
See details and how to joinNCT06519162
Phase 3Taking people
In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop
Where
Yongin-si
Age
19 years to 70 years
People
226
Run by
Green Cross Wellbeing
See details and how to joinNCT06493799
Phase 4Taking people
Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes
Where
Seongnam-si
Age
20 years and over
People
120
Run by
Seoul National University Bundang Hospital
See details and how to joinNCT06989723
No phaseTaking people
Establishment of NAFLD Cohort and Development of Fibrosis Markers
Where
Seoul
Age
18 years and over
People
1,000
Run by
Seoul National University Boramae Hospital
See details and how to joinNCT02206841
No phaseNot yet taking people in South Korea
Korean Health Screening-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Registry
Where
Gangwon-do, Gyeonggi-do, Seoul, Suwon, Yongin
Age
19 years and over
People
6,000
Run by
Korea University
See details and how to joinNCT06843421
No phaseTaking people
A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
Where
Andong, Seoul
Age
19 years and over
People
10,000
Run by
Boryung Pharmaceutical Co., Ltd
See details and how to joinNCT06649162
Phase 3Enrolling by invitation
Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy
Where
Seoul
Age
19 years to 74 years
People
196
Run by
Yoon Jun Kim
See details and how to joinNCT06152991